Sentences with phrase «develop resistance to this therapy»

Currently, if breast cancer cells develop resistance to these therapies, patients are usually treated with toxic chemotherapy agents that have significant side effects.

These cells often escape the reach of currently available cancer treatments, or even develop resistance to the therapies themselves.

«The earlier we can carry out the sequencing the better chance of identifying the right therapy before they develop resistance to therapies we could predict wouldn't work.

Not exact matches

These therapies have been modestly successful, but some patients fail to respond entirely and those who do respond almost inevitably develop resistance.

However, not everyone's melanoma will benefit equally from MAPK - targeted therapies, and initial benefits might wane over time as tumors develop resistance to treatment.

But in many cell lines and patient samples that developed resistance to the combination therapy, the researchers observed something different happening.

The analysis suggests that alternative therapies for certain mild infections — which may be easier to develop — could indirectly slow development of antibiotic resistance in more dangerous bugs.

Das explained that since the compounds they've developed make cancer cells more sensitive to attack, they also remove resistance to standard chemotherapy drugs — a serious problem in current therapies.

If these peptides are developed for therapeutic use, the researchers anticipate that they could be used either in stand - alone therapy or together with traditional antibiotics, which would make it more difficult for bacteria to evolve drug resistance.

One potential problem is that T. cruzi could quickly develop resistance to cecropin A: «If you try treating anything with single - agent therapy, resistance develops quite rapidly,» says Yale team member Ravi Duravasula.

To compensate for this shortcoming, combination therapy attempts to hit a virus at so many places simultaneously that it can not develop resistance to them alTo compensate for this shortcoming, combination therapy attempts to hit a virus at so many places simultaneously that it can not develop resistance to them alto hit a virus at so many places simultaneously that it can not develop resistance to them alto them all.

These so - called artemisinin combination therapies (ACTs)-- there are six combinations — are designed to stave off resistance, in much the same way that combinations curb HIV's ability to develop resistance to any single drug.

«We believe this discovery is a promising avenue for developing a new therapy to reduce chemo - resistance in women with this deadly disease,» said Dr. Dar - Bin Shieh, collaborative partner from National Cheng Kung University of Taiwan.

Sometimes they respond to renewed treatment, but then develop a resistance against all methods of therapy.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

In addition, the investigators found that among the HPTN 052 participants who started antiretroviral therapy early but failed treatment before May 2011, those who had a higher viral load when they joined the study were likely to develop resistance to their antiretroviral drugs.

Whilst further study is needed, we are building evidence to show that genetic diversity in a bacterial infection or in a tumour being treated could lay the foundation for resistance to the therapy and affect how quickly resistance develops.»

Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.

The authors said their results, which they have made publicly available, constitute an invaluable resource to help clinicians predict which chemotherapies will be most effective against tumor cells with particular genetic mutations, and how to rationally combine therapies to prevent cancers from developing resistance.

Field reports suggest that not all K13 mutations are capable of causing resistance, and the genetic system developed by Dr. Fidock to study K13, based on DNA repair approaches that are being used in human gene therapy studies, will be critical in identifying real hot spots of resistance.

The tumors often develop resistance to existing therapies, and in general only 50 % of people with the cancer live longer than 15 months.

However, these patients will eventually develop resistance to EGFR TKI therapy and a further EGFR mutation called T790M accounts for 60 % of this acquired resistance.

And while new therapies have been effective in releasing the immune system's restraints to unleash the body's own cancer - fighting powers, they only work in about half of melanoma patients and often lose their potency as the cancer develops resistance.

These findings identify specific BRCA1 mutations that are more likely to develop therapy resistance, which may lead to more accurate predictions and personalized treatments for breast and ovarian cancers.

Prof Soria will say: «Eventually, almost all lung cancer patients with EGFR mutations will develop resistance to currently available therapies, including TKI, leaving doctors and patients without effective options to treat this deadly disease.

The researchers say their method offers a new explanation for how to prevent cancer cells from becoming treatment - resistant and how combinations therapies can be developed to overcome drug resistance.

«Current therapies take advantage of this by using targeted drugs such as Trastuzumab or Lapatinib to specifically inhibit ERBB2, but eventually they become ineffective as the cancer develops resistance to those drugs.»

«Using a novel model we developed to facilitate discoveries about the growth and spread of lymph node metastases, we show that angiogenesis does not occur in lymph node metastases, providing a mechanism for resistance to angiogenic therapy in these situations.»

Shokat and his colleagues wanted to get ahead of this problem, and began thinking about third - generation mTOR inhibitors without waiting for patients to develop resistance to the latest therapies.

Such rapid and extensive degradation suggests that conjugates may be able to prevent or hinder cancer cells from developing resistance to targeted therapies, the researchers state.

«Figuring out why resistance to targeted therapies develops has been the focus of our research for a long time,» says Paul Mischel, the paper's co-corresponding author, at the Ludwig Institute for Cancer Research at the University of California, San Diego.

Researchers developed the strategy as a way to develop inhibitors of «undruggable» proteins and overcome drug resistance, a common shortcoming of targeted therapies.

«It would be very difficult for the virus to develop resistance against a therapy that targets a cellular protein,» says Palese.

«Given the alarming trend of resistance to our current antimalarial therapies, this is really an exciting finding,» says Dr. Mota, the senior author of the study, «and we are already working to develop Torin molecules suitable for clinical trials of antimalarial activity in humans.»

Wu added that in this respect, the response generated by a neoantigen vaccine is similar to the new wave of combination therapies, which are showing more promise in treating cancers that typically develop resistance to single drugs.

C. Develop ways to overcome cancer's resistance to therapy Identify therapeutic targets to overcome drug resistance through studies that determine the mechanisms that lead cancer cells to become resistant to previously effective treatments.

However, unfortunately, the vast majority of patients do not respond to checkpoint inhibition therapy and a minority of patients, who do respond to treatment, develop secondary resistance and experience relapse by mechanisms still inadequately understood.

A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development.

Trotman and his team, which included collaborators from Weill Cornell Medical College, Mt. Sinai School of Medicine and the Dana - Farber Cancer Institute, used RapidCaP to generate mice that developed metastatic prostate cancer with classic hallmarks of this disease, including resistance to hormone therapy.

However, many patients eventually develop resistance to these targeted therapies and their cancer comes back.

Currently he is developing treatment to prevent both resistance and toxicity, especially neurotoxicity from therapy.

These research studies improve our understanding of the disease by uncovering the mechanisms of response and resistance, potentially gaining insight that would allow us to predict the future patients who will benefit from each of these treatments and to develop new therapies that are even more effective.

This was encouraging since the cancer in all but 2 of the dogs had already developed resistance to other therapies.